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Abstract
Objective: To identify prognostic factors for short-term survival of dogs that
experience seizures within 7 days after surgical correction of single congenital
extrahepatic portosystemic shunts (cEHPSS).
Study design: Multi-institutional retrospective study.
Sample population: Ninety-three client-owned dogs.
Methods: Medical records at 14 veterinary institutions were reviewed to iden-
tify dogs that underwent surgical attenuation of a single cEHPSS from January
1, 2005 through February 28, 2018 and experienced postattenuation seizures
(PAS) within 7 days postoperatively. Logistic regression analysis was performed
to identify factors associated with 1-month survival. Factors investigated
included participating institution, signalment, shunt morphology, concurrent/
historical conditions, presence of preoperative neurologic signs, presence of pre-
operative seizures, aspects of preoperative medical management, surgical details
including method and degree of shunt attenuation, type of PAS (focal only or
generalized ± focal), drugs administered as part of the treatment of PAS, and
development of complications during treatment of PAS.
Results: Thirty (32.3%) dogs survived to 30 days. Seventy-six (81.7%) dogs
experienced generalized PAS. Factors positively associated with short-term sur-
vival included having a history of preoperative seizures (P = .004) and develop-
ment of focal PAS only (P = .0003). Most nonsurvivors were humanely
euthanized because of uncontrolled or recurrent seizures.
Conclusion: Dogs that experienced PAS that had a history of preoperative sei-
zures and those that experienced focal PAS only had significantly improved
short-term survival.
Clinical significance: The results of this study provide information that will
help in the counseling of owners who seek treatment for PAS after surgical cor-
rection of cEHPSS.
© 2020 The American College of Veterinary Surgeons.
1 | INTRODUCTION
Development of postattenuation seizures (PAS) is a well-
recognized complication of surgical correction of por-
tosystemic shunts in dogs,1-26 with often fatal conse-
quences.1-3,8-10,12,15,18,21,22 These seizures have an incidence
of up to 4.7%–8.1% reported in the recent literature18,21,22
and occur almost exclusively within 5 days postopera-
tively.1-26 The etiopathogenesis of PAS is not well under-
stood. Proposed theories include a decline in systemic
concentrations of endogenous benzodiazepines/benzodiaz-
epine-like substances, hypoglycemia, electrolyte derange-
ments (hypocalcemia and hypokalemia), hypoxemia,
exacerbation of hepatic encephalopathy, an unknown
perioperative metabolic event, sudden correction of an
adapted to altered metabolic state, systemic hypertension,
concurrent brain disease, intraoperative hypotension, and
prolonged surgical and anesthetic times.2,3,9,10,21,23,27 How-
ever, none of these has been consistently identified in previ-
ous studies.1-25 For instance, PAS have been reported in the
face of normal to only mildly elevated ammonia concentra-
tions2,7,9,10,17,20,22 and normal glucose7-10,17,20,21,23 and
electrolyte concentrations.17,20
Large-scale studies in which risk factors for PAS have
been investigated are lacking.9,22 In a recent study by
Strickland et al,22 increasing age and the presence of hepatic
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encephalopathy immediately preoperatively were identified
as risk factors for postoperative neurologic signs and sei-
zures. Occurrence of PAS has not been definitively shown
to be associated with shunt morphology (intrahepatic or
extrahepatic or individual submorphologies), presence of
preoperative seizures, or method or degree of shunt attenua-
tion.2,3,6,9,11,14-19,21,22 Certain breeds have been suggested as
being at greater risk of PAS including pugs,6,9,23 Maltese
terriers,1,2 and Jack Russell terriers.14
On the basis of a limited number of case reports, small
case series, and isolated cases within retrospective studies,
a guarded prognosis is typically provided after develop-
ment of PAS.1-3,8-10,12,15,18,21,22 The largest cohort of dogs
affected by PAS in a published study (in which 12 dogs
with PAS were described) was reported by Strickland
et al.22 In that study,22 which included dogs with congeni-
tal extrahepatic portosystemic shunts (cEHPSS) and con-
genital intrahepatic portosystemic shunts (cIHPSS), only
seven of 12 dogs that experienced PAS survived to dis-
charge. A number of authors, however, have reported a
more favorable prognosis.7,17,20,21 In one study,21 dogs that
experienced PAS that had a history of preoperative sei-
zures had improved survival compared with those that
had not had a history of preoperative seizures. There are
also reports of a more favorable outcome after treatment
of PAS with administration of continuous rate infusion
(CRI) of propofol.7,17,20 A limitation of these reports, how-
ever, has been the small study samples and the fact that
other antiepileptic drugs were administered concurrently
with propofol CRI, which makes interpretation difficult.
The objective of the study reported here was to iden-
tify prognostic factors for short-term survival of dogs
that experienced PAS within 7 days after surgical correc-
tion of single cEHPSS. We hypothesized that, having
received prophylactic levetiracetam (LEV), treatment of
PAS with propofol CRI, having experienced PAS/under-
gone surgery in the second half of the study period and
development of focal PAS only would be positively asso-
ciated with short-term survival.
2 | MATERIALS AND METHODS
2.1 | Inclusion and exclusion criteria
Medical records at 14 institutions were retrospectively
reviewed to identify dogs that underwent surgical attenua-
tion (suture ligation [SL], thin film banding [TFB], or amer-
oid ring constrictor [ARC] placement) of a single cEHPSS
from January 1, 2005 through February 28, 2018 and experi-
enced PAS within 7 days postoperatively. Exclusion criteria
included dogs with cIHPSS, dogs that did not undergo
shunt attenuation because of apparent concurrent portal
vein aplasia, and dogs that were lost to follow-up prior to
30 days postoperatively. Dogs that experienced onset of
seizure activity after 7 days postattenuation were excluded.
2.2 | Data collection
Data retrieved from medical records of dogs that met inclu-
sion criteria included breed, age, sex/neuter status, and
bodyweight at surgery; year of surgery; shunt morphology
(portocaval, portoazygos or portophrenic); concurrent/histori-
cal conditions at presentation; presence and type of preopera-
tive neurologic signs and seizures; abnormal preoperative
physical examination findings; method of shunt identifica-
tion (abdominal ultrasound, computed tomography angiog-
raphy [CTA], magnetic resonance imaging [MRI],
intraoperative portovenography [IOPV], nuclear scintigra-
phy); details of preoperative medical management; prophy-
lactic LEV or other antiseizure medications; method (SL,
TFB or ARC) and degree (complete, partial, or none) of acute
intraoperative shunt attenuation; timing and type of PAS
(focal only or generalized ± focal); electrolyte (sodium, potas-
sium and chloride), glucose, and ammonia concentrations
about the time of PAS occurrence; antiseizure medications
administered as part of treatment of PAS; complications
experienced during treatment of PAS; and whether the dog
survived to 1 month. Regarding preoperative medical man-
agement, dogs were recorded as having received at least
1 week's duration of preoperative lactulose or not and at least
1 week's duration of antimicrobials or not. Preoperative diet
type was also recorded. Dogs were divided into four groups
with respect to prophylactic treatment with LEV: received
no LEV (LEV−); received LEV at ≥20 mg/kg every
8 hours for ≥24 hours preoperatively or 60 mg/kg IV
loading dose of LEV perioperatively, and continued at
≥20 mg/kg every 8 hours postoperatively (LEV1);
received LEV at <20 mg/kg every 8 hours for <24 hours
preoperatively, or continued at <20 mg/kg every 8 hours
postoperatively (LEV2); and received LEV postopera-
tively only (but prior to postoperative seizure activity)
according to the same preoperative protocol of group
LEV1 (LEV3). Short-term survival was defined as sur-
vival to 30 days. For dogs that did not survive to 30 days,
whether the dog had died naturally or had been
humanely euthanized and the cause/reason were
recorded. A complication was defined as any unantici-
pated event that altered the course of PAS treatment.
2.3 | Statistical analyses
Continuous variables were tested for normality by using
graphical methods, skewness, kurtosis, and Shapiro–Wilk
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test. Normally and nonnormally distributed continuous vari-
ables were presented as mean and SD and median and range,
respectively. Categorical variables were presented as fre-
quency and percentages (with 95% confidence interval [CI]).
Comparison of electrolyte, glucose, and ammonia concentra-
tions between survivors and nonsurvivors and dogs with and
without a history of preoperative seizures were made by
using the independent samples t test or Mann–Whitney
U test, depending on normality of the data. Univariable logis-
tic regression analysis was performed to assess for factor asso-
ciation with 1-month survival. Factors assessed included
contributing institution, breed, sex/neuter status, age, and
bodyweight at surgery; year of surgery; shunt morphology;
presence of preoperative neurologic signs; presence of preop-
erative seizure activity; presence of concurrent/historical con-
ditions at presentation; whether the dog received a minimum
of 1 week's duration of preoperative lactulose; whether the
dog received a minimum of 1 week's duration of preoperative
antimicrobials; LEV group (LEV−, LEV1, LEV2 or LEV3);
method of shunt attenuation and degree of acute
intraoperative shunt attenuation (complete, partial or none);
whether the dog developed generalized or focal PAS only;
and whether the dog experienced a complication during
treatment of PAS. The second half of the study period was
defined as January 1, 2012 onward. Additional factors that
were assessed included treatment of PAS with propofol
CRI, alfaxalone CRI, benzodiazepine, LEV, phenobarbital,
potassium bromide, α-2 agonist, gabapentin/pregabalin,
flumazenil, and mannitol. Multivariable logistic regression
analysis was performed to assess all variables identified with
P < .2 in the univariable analysis. Backward selection was
used with a retention α of .05 for variables to be retained in
the model. This allowed calculation of adjusted odds ratios
and 95% CI. Statistical analysis was performed in SAS ver-
sion 9.4 (SAS Institute, Cary, North Carolina). Statistical sig-
nificance was set at P < .05.
3 | RESULTS
Ninety-three dogs were included in the study. Details of
75 dogs are the subject of another report. Details of 16 dogs
have partially been reported previously.17,18,20,21,26
3.1 | Signalment
Breeds included mixed breed (n = 18), Yorkshire terrier
(n = 15), bichon frise (n = 12), pug (n = 9), shih tzu
(n = 8), Maltese terrier (n = 6), Jack Russell terrier
(n = 6), miniature schnauzer (n = 5), Chihuahua
(n = 4), dachshund (n = 3), West Highland white terrier
(n = 2), and one each of Norfolk terrier, border terrier,
Brussels griffon, Coton De Tulear, and setter. There
were 31 (33.3%) spayed females, 13 (14.0%) intact
females, two (2.2%) unspecified females, 28 (30.1%) cas-
trated males, and 19 (20.4%) intact males. Median
(range) age was 34 (5-124) months. Median (range)
weight was 6 (1.4-21.0) kg.
3.2 | Year of surgery
Thirty-three (35.5%) dogs experienced PAS from January
2005 through December 2011 (first half of study period),
and 60 (64.5%) dogs experienced PAS from January 2012
through February 2018.
3.3 | Historical neurologic signs and
seizures
Preoperative neurologic signs were recorded in 73 of
93 (78.5%) dogs. Preoperative seizures were recorded in
16 of 93 (17.2%) dogs. The most common neurologic signs
included reduced mentation (n = 46), pacing/wandering/
compulsive walking (n = 15), ataxia (n = 12), abnormal
behavior/behavior change (n = 11), head pressing (n = 9),
hypersalivation/drooling (n=9), circling (n=8), disorienta-
tion (n = 5), and four each of increased/inappropriate
sleeping/sleepy, apparent blindness, and weakness.
3.4 | Concurrent/historical conditions at
presentation
Concurrent/historical conditions at presentation were
recorded in 27 of 93 (29.0%) dogs and most commonly
included urolithiasis (n = 19); urinary tract infection
(n = 8); cardiac murmur (n = 4); unspecified brachyce-
phalic airway syndrome; and one each of urinary sedi-
ment/crystalluria, pattern baldness, distichiasis, and
cryptorchidism. Two dogs had previously undergone
cEHPSS attenuation 7 and 16 months prior but did not
experience PAS after initial surgery.
3.5 | Method of shunt identification and
morphology
Shunts were identified preoperatively by ultrasonography
(n = 75), CTA (n = 31), nuclear scintigraphy (n = 3),
and/or MRI (n = 1). Seventeen dogs underwent IOPV.
Shunt morphology was available for 89 of 93 (95.7%) dogs
and included portocaval (n = 67), portoazygos (n = 16),
and portophrenic (n = 6).
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3.6 | Preoperative medical management
Ninety-one (97.8%) dogs received preoperative medical
management, which included combinations of antimicro-
bials, lactulose, and a protein-restricted diet. One dog did
not receive preoperative medical management. For the
remaining dog, this information could not be confirmed.
Seventy-eight (83.9%) dogs received at least 1 week of
preoperative antimicrobial. Eighty-one (87.1%) dogs
received at least 1 week of preoperative lactulose. Fifty-
seven dogs received a prescription hepatic diet, eight dogs
received an unspecified protein-restricted diet, and five
dogs received a protein-restricted renal diet. Other diets
included hypoallergenic (n = 3), vegetarian (n = 2),
homemade protein-restricted (n = 2); one dog received a
gastrointestinal diet, and one dog received a homemade
chicken and vegetable diet. For the remaining dogs, the
type of diet was not recorded.
3.7 | Prophylactic LEV or other
antiseizure medications
Fifty (53.8%) dogs had received prophylactic LEV. One
of these dogs had received additional prophylactic
treatment with phenobarbital (3 mg/kg every 12 hours)
and potassium bromide (8 mg/kg every 24 hours) for
3 months preoperatively. Forty-three (46.2%), 22 (23.7%),
25 (26.9%) and three (3.2%) dogs were included in groups
LEV−, LEV1, LEV2 and LEV3, respectively.
3.8 | Preoperative physical examination
findings
Preoperative physical examination findings were avail-
able for 86 of 93 (92.5%) dogs. Abnormal findings were
recorded in 48 of 86 (55.8%) dogs and most commonly
included reduced/altered mentation/lethargy (n = 22),
underweight/suboptimal body condition (n = 16), small
stature (n = 7), ataxia (n = 6), circling (n = 4), pacing/
wandering (n = 3), and cardiac murmur (n = 3).
3.9 | Method and degree of shunt
attenuation
Shunts were attenuated by using TFB (n = 36: partial
attenuation [n = 20], no attenuation [n = 16]), ARC
(n = 33: no attenuation [n = 33]), SL (n = 23: complete
attenuation [n = 20], partial attenuation [n = 3]), and
combination of TFB and suture (n = 1: partial attenua-
tion [n = 1]). T
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3.10 | Type and timing of PAS
Seventy-six (81.7%) dogs were recorded as having devel-
oped generalized PAS, while 17 (18.3%) dogs developed
focal PAS only. Among the 76 dogs that experienced gen-
eralized PAS, 13 (17.1%) were recorded as having experi-
enced focal PAS that later progressed to generalized
despite treatment. Postattenuation seizures commenced
after a median (range) of 48 (3-144) hours postopera-
tively. Seventy-three (78.5%) dogs developed PAS while
hospitalized. Twenty (21.5%) dogs displayed neurologic
signs/commenced seizure activity postdischarge.
3.11 | Electrolyte, glucose, and ammonia
concentrations at the time of PAS
Electrolyte, glucose, and ammonia concentrations overall
(when available), among survivors and nonsurvivors and
dogs with and without a history of preoperative seizures
TABLE 2 Reason for euthanasia, cause of natural death, and complications during treatment of PAS
Event Explanation
Cause of natural deatha Cardiorespiratory arrest, n = 5
Aspiration pneumonia, n = 1
Suspect cerebrocortical necrosis secondary to severe
hypernatremia and hyperchloremia, n = 1
Spontaneous death, n = 1
Heart failure, pulmonary edema, n = 1
Reason for euthanasiaa Uncontrolled or recurrent seizures, n = 24
Persistent seizures and poor prognosis, n = 8
Uncontrolled seizures ± financial limitations to ascertain whether
seizures would eventually cease, n = 5
Respiratory arrest, n = 2
Poor mentation, n = 1
Blind, unable to stand, welfare concerns, n = 1
Disorientated, vocalizing, and nonresponsive, n = 1
Seizures, suspected aspiration pneumonia, n = 1
Seizures, hypoventilation, and poor prognosis, n = 1
Seizures, unresponsive, and fulminant liver failure, n = 1
Suspected portal hypertension, n = 1
Aspiration pneumonia, n = 1
Uncontrolled neurologic signs, n = 1
Uncontrolled seizures and pulmonary edema, n = 1
Unsuccessful reanimation, n = 1
Seizures, coma, n = 1
Complications during
treatment of PAS
Aspiration pneumonia, n = 4
Pyrexia, respiratory arrest and aspiration pneumonia, n = 1
Aspiration pneumonia and suspect thromboembolic event, n = 1
Acute renal failure, cardiogenic edema, and pneumonia, n = 1
Repeated respiratory arrest, n = 1
Hypoventilation requiring mechanical ventilation, n = 1
Hypoventilation requiring mechanical ventilation, suspected
vagal event, hypertension and tachycardia, respiratory arrest, n = 1
Fulminant liver failure, n = 1
Hyperthermia, tachycardia, hematochezia suspected related
to portal hypertension, no mesenteric congestion at revision coeliotomy, n = 1
Sepsis suspected to be associated with gastrostomy tube, n = 1
Sepsis, systemic inflammatory response syndrome, disseminated
intravascular coagulation, suspect pneumonia, requirement for
mechanical ventilation, n = 1
Pulmonary edema, n = 1
Pulmonary edema, hypothermia, and hyperthermia, n = 1
Abbreviation: PAS, postattenuation seizure.
aNot recorded if died or euthanized (n = 3).
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TABLE 3 Univariable regression analysis of variables potentially associated with survival to 30 days
Variable Categorya n %a Survivors, na Nonsurvivors, na P-value
Center .48
Age Median (range), mo 93 34 (5-124) 34.5 (5-64) 34 (6-124) .15
Weight Median (range), kg 93 6 (1.4-21) 6.0 (1.4-8.9) 6.0 (1.8-21.0) .16
Breed Mixed breed 18 19.4 4 18 .98
Yorkshire terrier 15 16.1 7 8
Bichon frise 12 12.9 6 6
Shih tzu 8 8.6 1 7
Maltese terrier 6 6.5 1 5
Pug 9 9.7 3 6
Miniature schnauzer 5 5.4
2 3
Jack Russell terrier 6 6.5
2 4
Dachshund 3 3.2 0 3
Chihuahua 4 4.3 1 3
West Highland white terrier 2 2.2 1 1
Norfolk terrier 1 1.1 1 0
Border terrier 1 1.1 1 0
Brussels griffon 1 1.1 0 1
Coton De Tulear 1 1.1 0 1
Setter 1 1.1 0 1
Sex ME 19 20.4 6 13 .64
MN 28 30.1 6 22
FE 13 14.0 5 8
FS 31 33.3 12 19
UF 2 2.2 1 1
Shunt morphology Portocaval 67 72.0 24 43 .99
portoazygos 16 17.2 6 10
Portophrenic 6 6.5 0 6
Unspecified 4 4.3 0 4
Concurrent/historical
conditions
Yes 27 29.0
9 18
.89
No 66 71.0 21 45
Preoperative
neurologic signs
Yes 73 78.5
27 46
.07
No 20 21.5 3 17
Preoperative seizures Yes 16 17.2 12 4 .0003
No 77 82.8 18 59
Preop antimicrobials
for minimum of 1 wk
Yes 78 83.9
29 49
.18
No 13 13.9 1 12
Unknown 2 2.2 0 2
Preop lactulose
for minimum of 1 wk
Yes 81 87.1
30 51
.99
No 10 10.7 0 10
(Continues)
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are presented in Table 1. No differences in these parame-
ters were identified between survivors vs nonsurvivors or
dogs with a history of preoperative seizures vs dogs with-
out a history of preoperative seizures (Table 1).
3.12 | Treatment of PAS
Ninety (96.8%) dogs received treatment for PAS. One
dog that experienced focal PAS only did not receive any
antiseizure treatment. An additional dog that experi-
enced focal PAS only did not receive any additional
treatment apart from continued administration of LEV.
One dog that experienced a generalized seizure at home
was already receiving LEV but did not receive any addi-
tional treatment. Specific details of drugs administered
as part of the treatment of PAS were available for all
but one dog. One dog that was receiving prophylactic
LEV experienced generalized PAS treated by the pri-
mary veterinarian. Specific details regarding additional
TABLE 3 (Continued)
Variable Categorya n %a Survivors, na Nonsurvivors, na P-value
Unknown 2 2.2 0 2
Prophylactic LEV LEV- 43 46.2 15 28 .2
LEV1 22 23.7 10 12
LEV2 25 26.9 4 21
LEV3 3 3.2 1 2
Year of surgery 2005 2 2.2 0 2 .94
2006 3 3.2 2 1
2007 1 1.1 0 1
2008 5 5.4 1 4
2009 2 2.2 0 2
2010 10 10.8 6 4
2011 10 10.8 3 7
2012 14 15.1 5 9
2013 12 12.9 4 8
2014 6 6.5 1 5
2015 12 12.9 3 9
2016 12 12.9 3 9
2017 3 3.2 1 2
2018 1 1.1 1 0
Surgery from
January 1, 2012 onward
Yes 60 64.5
18 42
.53
No 33 35.5 12 21
Method of shunt attenuation SL 23 24.7 6 17 .52
TFB 36 38.7 10 26
ARC 33 35.5 14 19
SL and TFB 1 1.1 0 1
Degree of Intraop
attenuation
None 49 52.7
17 32
.87
Partial 24 25.8 7 17
Complete 20 21.5 6 14
Type of postattenuation seizures Generalized 76 81.7 16 60 <.0001
Focal only 17 18.3 14 3
Abbreviations: ARC, Ameroid ring constrictor; F, female; FE, female entire; FS, female spayed; Intraop, intraoperative; LEV; levetiracetam; ME, male entire;
MN, male neutered; Preop, preoperative; SL, suture ligation; TFB, thin film banding; UF, unspecified female.
aExcept for age and weight.
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antiseizure medications administered were not avail-
able. Among 20 (21.5%) dogs that commenced seizure
activity postdischarge, nine (45.0%; 9.7% of all dogs)
were treated for PAS by their local veterinarian, eight
(40.0%; 8.6% of all dogs) were re-presented to the partic-
ipating institution, two (10%) were treated initially by
the local veterinarian and subsequently re-presented,
and the remaining dog was treated for generalized PAS
with continued administration of LEV by the owner
at home.
3.13 | Focal seizures only
Dogs that experienced focal PAS only were treated with
LEV (n = 15; 10 dogs were already receiving prophylactic
LEV: LEV1 [n = 6], LEV2 [n = 4]), benzodiazepines
(n = 9), propofol CRI (n = 6), phenobarbital (n = 6),
potassium bromide (n = 3), flumazenil (n = 2), α-2 ago-
nist (n = 1), and/or gabapentin (n = 1). One dog was
taken back to surgery to have the TFB removed because
of concerns over possible portal hypertension; moderate
TABLE 4 Univariable analysis of drugs administered as part of treatment of PAS
Variable Category n % Survivors, n Nonsurvivors, n P-value
Propofol CRI Yes 49 52.7 12 37 .21
No 43 46.2 18 25
Unknown 1 1.1 0 1
Alfaxalone CRI Yes 3 3.2 0 3 >.99
No 89 95.7 30 59
Unknown 1 1.1 0 1
Mannitol Yes 16 17.2 3 13 .44
No 76 81.7 27 49
Unknown 1 1.1 0 1
Benzodiazepines Yes 45 48.4 11 34 .27
No 47 50.5 19 28
Unknown 1 1.1 0 1
Levetiracetam Yes 64 68.8 22 42 .52
No 29 31.2 8 21
Phenobarbital Yes 55 59.1 16 39 .68
No 37 39.8 14 23
Unknown 1 1.1 0 1
Potassium bromide Yes 13 14.0 7 6 .23
No 79 85.0 23 56
Unknown 1 1.1 0 1
α-2 agonist Yes 8 8.6 4 4 .56
No 84 90.3 26 58
Unknown 1 1.1 0 1
Gabapentin/pregabalin Yes 4 4.3 2 2 .45
No 88 94.6 28 60
Unknown 1 1.1 0 1
Flumazenil Yes 2 2.2 2 0 .98
No 91 97.8 28 63
Unknown 1 1.1 0 1
Complication during treatment of PAS Yes 16 17.2 2 14 .08
No 77 82.8 28 49
Abbreviations: CRI: continuous rate infusion; PAS, postattenuation seizures.
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liver congestion was noted at surgery but without conges-
tion of mesenteric vessels. The dog was euthanized intra-
operatively at the request of the owners.
3.14 | Generalized seizures
Dogs that experienced generalized PAS were treated with
LEV (n = 49; 34 were already receiving prophylactic
LEV: LEV1 [n = 16], LEV2 [n = 21], LEV3 [n = 3]), phe-
nobarbital (n = 49; one dog was already receiving pro-
phylactic phenobarbital), propofol CRI (n = 43),
benzodiazepines (n = 36), mannitol (n = 16), potassium
bromide (n = 10; one dog was already receiving prophy-
lactic potassium bromide), α-2 agonist (n = 7), alfaxalone
CRI (n = 3), and/or gabapentin/pregabalin (n = 3).
3.15 | Development of complications
during treatment of PAS
Sixteen (17.2%) dogs experienced one or more significant
complications during treatment of PAS within 30 days
postoperatively (Table 2). The most common complica-
tion was development of aspiration pneumonia.
3.16 | Short-term survival
Thirty (32.3%) dogs survived to 30 days. Sixteen (21.1%)
of 76 dogs that experienced generalized (+/− focal) PAS
survived to 30 days, whereas 14 (82.4%) of 17 dogs that
experienced focal PAS only survived to 30 days. Among
those that did not survive, 50 (79.4%) were humanely
euthanized (generalised PAS [n = 48]; focal PAS only [n
= 2]), nine (14.3%) died (generalized PAS [n = 9]), and
one (1.6%) suffered cardiorespiratory arrest and was suc-
cessfully resuscitated but later euthanized (generalized
PAS [n = 1]). For the remaining three (4.8%) dogs, it was
not recorded whether they had died or been euthanized.
The most common reason for euthanasia was uncon-
trolled or recurrent seizures (Table 2). Median (range)
survival time of nonsurvivors was 4 (1-20) days (recorded
as 2-3 weeks postoperatively [n = 1]). Among those that
survived to 30 days, 16 experienced generalized PAS,
14 experienced focal PAS only. Sixty dogs that did not
survive to 30 days experienced generalized PAS, while
three dogs experienced focal PAS only. Cause of natural
death and reasons for humane euthanasia are presented
in Table 2.
3.17 | Prognostic factors associated
with short-term survival
Results of univariable analysis are presented in Tables 3
and 4. Prophylactic treatment with LEV, surgery per-
formed in the second half of the study period, and treat-
ment of PAS with propofol CRI were not associated with
short-term survival. Factors associated with short-term
survival in the multivariable analysis included having a
history of preoperative seizures (P = .004) and type of PAS
(P = .0003; Table 5). Dogs with a history of preoperative
seizures had 7.6-fold (95% CI: 1.9-30.3) increased odds of
survival to 30 days compared with those without a history
of preoperative seizures, with adjustment for PAS type.
Dogs that developed focal PAS only had increased odds of
survival (odds ratio = 14.4, (95% CI: 3.4-60.2)) compared
with those that experienced generalized PAS, with adjust-
ment for preoperative seizure activity.
4 | DISCUSSION
The main findings of this study are (1) that affected dogs
that had a history of preoperative seizures and those that
experienced focal PAS only had significantly increased
odds of survival to 30 days and (2) having received pro-
phylactic treatment with LEV, treatment of PAS with
propofol CRI and having experienced PAS/undergone
surgery in the second half of the study period were not
associated with improved short-term survival.
In a recent study by Brunson et al,21 dogs that experi-
enced PAS that had a history of preoperative seizure activity
had a sevenfold increased probability of survival compared
with those that had not had a history of preoperative seizure
activity. Similarly in our study, such dogs had an almost
eightfold increased odds of survival to 30 days. One possible
explanation for this is that PAS experienced by both of these
subsets of dogs have a different etiopathogenesis or that
TABLE 5 Multivariable logistic
regression model assessing relationship
with outcome of survival to 30 days
Variable Category OR 95% CI P-value
Preop seizures Yes 7.6 1.9-30.3 .004
No Reference
Type of PAS Focal only 14.4 3.4-60.2 .0003
Generalized ± focal Reference
Abbreviations: CI, confidence interval; OR, odds ratio; PAS, postattenuation seizures; Preop, preoperative.
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some dogs with a history of preoperative seizure activity
have continuation of these seizures postoperatively. We did
not find support for hyperammonemia to be responsible for
PAS in such affected dogs in our study, which is in line with
reports by several other investigators.2,7,9,10,17,20,22 It is well
recognized that ammonia concentrations and severity of
encephalopathy do not always correlate, emphasizing the
importance of other neurotoxic substances.28 In a study by
Strickland et al,22 the presence of hepatic encephalopathy
immediately preoperatively was identified as a risk factor
for PAS; however, similar to our results, postoperative
ammonia concentrations were normal to mildly elevated in
all dogs for which it was available.
Dogs that experienced focal PAS only in our study
had a 14.4-fold increased odds of short-term survival
compared with those that experienced generalized PAS.
Whether focal PAS in such affected dogs represent a less
aggressive form of neurologic dysfunction, has a different
etiopathogenesis, or would have progressed to general-
ized PAS without antiseizure treatment is unknown. Sev-
enteen percent of dogs that developed generalized PAS in
our study were recorded as having experienced initial
focal PAS, which provides evidence that these may be a
precursor to generalized PAS in some cases. In a study by
Mehl et al,15 all dogs that experienced focal PAS only sur-
vived to discharge, while all those that experienced gener-
alized PAS within 7 days postoperatively died during
hospitalization. Most dogs that failed to survive to 30 days
in our study were humanely euthanized, most commonly
because of uncontrolled or recurrent seizures (Table 2). It
is possible that factors such as client unwillingness to
continue treatment, financial constraints, or an attending
clinician's perception of a poor prognosis for neurologic
recovery significantly influenced the decision to eutha-
nize. It may be anticipated that generalized PAS is more
challenging to abolish, more distressing for the pet owner
to observe, and associated with a greater treatment cost
and the perception of a poorer prognosis for recovery, all
of which may provoke a decision to euthanize.
Only one-third of dogs that experienced PAS in our
study survived to 30 days, which is in line with previous
reports of 0% to 58.3% in the literature.2,3,9,15,18,21,22 The
large proportion (81.7%) of dogs in our study that experi-
enced generalized PAS had a strong influence on the low
short-term survival rate because such dogs had signifi-
cantly decreased odds of survival in the multivariable
analysis.
We hypothesized that having undergone surgery/
experienced PAS in the second half of the study period
would be positively associated with short-term survival.
This was based on the premise that, with greater experi-
ence in treating PAS and advances in critical care medi-
cine, short-term survival would be improved. This was
not supported by the results of our study. Possible expla-
nations for this may be related to factors such as a per-
ceived poor prognosis for neurologic recovery, factors
outside of the control of the attending clinician including
client unwillingness to pursue treatment and financial
constraints, and the overall infrequent occurrence of
PAS. In our study, the maximum number of cases of PAS
seen by any institution in a single year was four, with
most institutions seeing a maximum of one or two cases
per year.
Administration of several antiepileptic drugs including
benzodiazepines,2,3,9-12,14,15 barbiturates,2,3,6-12,14,15 and
propofol7,10,14,17 has been described for the treatment of
PAS in previous reports. There are, however, no large-scale
studies in which researchers have compared outcomes of
affected dogs treated with various antiepileptic drugs,
likely because of the infrequent occurrence of these sei-
zures and subsequent small case numbers within individ-
ual institutions.22 In our study, none of these antiepileptic
drugs, including propofol CRI, was associated with short-
term survival. Because of the nonprospective nature of our
study, treatment of PAS with propofol CRI was not ran-
domized. Therefore, it is likely that it will have been
administered to the most severely affected cases in our
study. While there are reports of a more favorable progno-
sis with administration of propofol CRI,7,17,20 individual
numbers are small and may represent a positive outcome
publication bias. Previous studies have reported conflicting
results regarding the possible protective effect of LEV
against development of PAS.18,21,22,26 Approximately half
of the dogs in our study received prophylactic LEV. The
recommended dose of LEV is 20 mg/kg orally every
8 hours for a minimum of 24 hours preoperatively.27 On
the basis of the known pharmacokinetics of the drug
(albeit in healthy dogs), continuation of the drug at the
same dose during the first 7 days postoperatively should
be considered.29 Several dogs in our study received less
standardized protocols of LEV (groups LEV2 and LEV3).
No group, however, was of prognostic significance. It is
possible that dogs that develop PAS despite receiving pro-
phylactic treatment with LEV are biased toward more
severe postattenuation neurologic dysfunction, although
this is purely speculative. It also raises the question
whether continued treatment of such dogs with LEV after
development of PAS is likely to be of benefit.
This study has a number of important limitations. Sim-
ilar to all retrospective studies, the accuracy of the pres-
ented data relies on the completeness of the medical
records. Seventy-five of the dogs of the present report are
the subject of another study which investigated the effect
of prophylactic treatment with LEV on the incidence of
PAS in dogs that underwent cEHPSS attenuation.26
Because of the infrequent occurrence of PAS, the present
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study would not have been possible without the inclusion
of such dogs. This was a multicenter study involving multi-
ple surgeons, with differences in case management and
experience in treating PAS. Treatment of PAS with differ-
ent antiepileptic drugs was not randomized but rather
based on clinician preference. Drug dosages and infusion
dose rates were not standardized. We did not record indi-
vidual doses of various antiepileptic drugs used to treat
PAS because these will have varied widely even within
individual dogs, with most dogs receiving numerous
boluses of individual drugs along with variable rates of
CRI. Other factors including the attending clinician's per-
ception of prognosis for neurologic recovery after develop-
ment of PAS, the extent to which the seizures were
treated, cost of treatment, and client willingness to treat
seizures could not be controlled because of the retrospec-
tive nature of the study. The authors acknowledge that
several of the dogs included in this study may have experi-
enced prodromal neurologic signs prior to seizure onset;
however, because of the retrospective nature of the study,
the exact timing and details of such sign may not have
been accurately recorded in the medical record. Addition-
ally, the timings of when the antiseizure medications were
started in relation to prodromal neurologic signs or follow-
ing the occurrence of actual seizures was not possible to
determine from the retrospective nature of our study. The
classification of seizures as focal or generalized in this
study reflects what was recorded in the medical record.
Assignment of a dog as having experienced a seizure was
based on the attending clinician's/criticalist's interpreta-
tion of the neurologic signs manifested. However, it is
important to note that all dogs were treated at academic
teaching hospitals or referral institutions by multi-
disciplinary staff with extensive experience in treating dogs
with portosystemic shunts and their complications.
Finally, just under 10% of dogs that experienced PAS in
this study were not treated for PAS at the operating institu-
tion, and the impact of this on the survival of such dogs is
unknown.
The overall short-term survival rate in this study
was low, with just under one-third of dogs surviving to
30 days. Affected dogs that had a history of preopera-
tive seizures or experienced focal PAS only had signifi-
cantly improved short-term survival. The results of this
study provide information that will help in the
counseling of owners who seek treatment for cEHPSS
for their animals and may serve as a basis for further
investigation regarding prevention or treatment of PAS
in the future.
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